

# Emerging Challenges In Primary Care: 2012

#### **Activity Evaluation Summary**

**CME Activity:** Emerging Challenges in Primary Care: 2012

Saturday, August 25, 2012 Hyatt Regency Baltimore

Baltimore, MD

Course Director: Gregg Sherman, MD

**Date of Evaluation** 

**Summary:** 

September 10, 2012



In August 2012, the National Association for Continuing Education (NACE) sponsored a CME program, *Emerging Challenges in Primary Care: 2012*, in Baltimore, MD.

This educational activity was designed to provide primary care physicians, nurse practitioners, physician assistants and other primary care providers the opportunity to learn about Diabetes, Atrial Fibrillation, Inflammatory Bowel Disease, Osteoporosis, Pulmonary Arterial Hypertension, Alpha-1 Antitrypsin Disorder, and ADHD in Adults.

In planning this CME activity, the NACE performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance.

Two hundred thirty five healthcare practitioners registered to attend *Emerging Challenges in Primary Care: 2012* in Baltimore, MD. One forty nine healthcare practitioners actually attended this conference. Each attendee was asked to complete and return an activity evaluation form prior to the end of the conference. One hundred forty four completed forms were received. The data collected is displayed in this report.


#### CME ACCREDITATION

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 7 AMA PRA Category 1 Credits<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


#### What is your professional degree?

Label	Frequency	Percent	Valid
			Percent
MD	110	76.39	76.92
DO	4	2.78	2.80
NP	13	9.03	9.09
PA	13	9.03	9.09
RN	1	0.69	0.70
Other	2	1.39	1.40
Total Valid	143	99.31	100.00
Total Missing	1	0.69	
Total	144	100.00	




#### What is your specialty?

Label	Frequency	Percent	Valid
			Percent
Primary Care	107	74.31	74.31
Endocrinology	1	0.69	0.69
Rheumatology	0	0.00	0.00
Pulmonology	2	1.39	1.39
Cardiology	3	2.08	2.08
Gastroenterology	2	1.39	1.39
OB/GYN	4	2.78	2.78
Other	25	17.36	17.36
Total Valid	144	100.00	100.00




Upon completion of this activity, I can now - Address the importance of early diagnosis for enhancing outcomes in type 2 diabetes; identify evidence-based strategies for type 2 diabetes management; discuss the role of newer therapies in the pathophysiology and management of type 2 diabetes; and discuss the role of the chronic care model in optimizing diabetes care:

Label	Frequency	Percent	Valid
			Percent
Yes	124	86.11	86.71
Somewhat	19	13.19	13.29
Not at all	0	0.00	0.00
Total Valid	143	99.31	100.00
Total Missing	1	0.69	
Total	144	100.00	




Upon completion of this activity, I can now - Discuss screening strategies for osteoporosis in postmenopausal women; identify candidates for pharmacologic treatment of postmenopausal osteoporosis; evaluate and compare available therapies for osteoporosis; and discuss barriers to adherence and effectiveness of osteoporosis therapy:

Label	Frequency	Percent	Valid
			Percent
Yes	134	93.06	93.71
Somewhat	9	6.25	6.29
Not at all	0	0.00	0.00
Total Valid	143	99.31	100.00
Total Missing	1	0.69	
Total	144	100.00	




Upon completion of this activity, I can now - Describe existing guidelines and best practices in the diagnosis and treatment of ADHD in adults; identify risks for co-morbidities in adult patients with ADHD with emphasis on anxiety disorders, mood disorders, and substance use/abuse disoeders; plan a pharmacologic treatment program for adults diagnosed with simple ADHD and more complex ADHD that is complicated by co-morbidities; identify psychosocial treatments for adults diagnosed with ADHD:

Label	Frequency	Percent	Valid
			Percent
Yes	108	75.00	75.00
Somewhat	34	23.61	23.61
Not at all	2	1.39	1.39
Total Valid	144	100.00	100.00




Upon completion of this activity, I can now - Use the CHADS2 score to assess stroke risk in patients with atrial fibrillation (AF); describe the benefits versus risks of antithrombotic therapy for stroke risk reduction in AF patients; identify appropriate therapeutic interventions for AF patients depending on the level of stroke risk; optimize the long-term management of AF patients receiving antithrombotic therapy:

Label	Frequency	Percent	Valid
			Percent
Yes	125	86.81	86.81
Somewhat	18	12.50	12.50
Not at all	1	0.69	0.69
Total Valid	144	100.00	100.00




Upon completion of this activity, I can now - Address the pathophysiology of PAH; discuss when and how to screen patients for PAH; identify current therapies in the management of PAH; and discuss how to appropriately monitor patients receiving treatment for PAH:

Label	Frequency	Percent	Valid
			Percent
Yes	101	70.14	75.37
Somewhat	30	20.83	22.39
Not at all	3	2.08	2.24
Total Valid	134	93.06	100.00
Total Missing	10	6.94	
Total	144	100.00	




Upon completion of this activity, I can now - Describe the pathophysiology and impact of AAT deficiency; Define approaches for the early identification of patients with AAT deficiency; Discuss strategies to improve testing in primary care settings; Discuss management of patients with AAT:

Label	Frequency	Percent	Valid
			Percent
Yes	96	66.67	76.19
Somewhat	26	18.06	20.63
Not at all	4	2.78	3.17
Total Valid	126	87.50	100.00
Total Missing	18	12.50	
Total	144	100.00	




Upon completion of this activity, I can now - Identify the conditions referred to as inflammatory bowel disease (IBD), and discuss their clinical presentations; implement appropriate pharmacologic and non-pharmacologic therapeutic strategies for managing IBD in accordance with evidence-based guidelines; tailor the available medications to the various presentations of IBD with attention to the induction and the maintenance of remission; use currently available laboratory tests to maximize benefit while minimizing toxicity; employ approaches for effectively communicating the risks and benefits of IBD treatment options and facilitating adherence:

Label	Frequency	Percent	Valid
			Percent
Yes	91	63.19	85.05
Somewhat	14	9.72	13.08
Not at all	2	1.39	1.87
Total Valid	107	74.31	100.00
Total Missing	37	25.69	
Total	144	100.00	




#### Overall, I would rate this activity as:

Label	Frequency	Percent	Valid
			Percent
Excellent	78	54.17	54.17
Very Good	54	37.50	37.50
Good	10	6.94	6.94
Fair	2	1.39	1.39
Poor	0	0.00	0.00
Total Valid	144	100.00	100.00




### Overall, this activity was effective in enhancing my confidence in caring for patients with the condition(s) presented?

Label	Frequency	Percent	Valid
			Percent
Strongly Agree	78	54.17	54.17
Agree	61	42.36	42.36
Neutral	5	3.47	3.47
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	144	100.00	100.00




### Overall, this activity was effective in improving my knowledge in the content areas presented:

Label	Frequency	Percent	Valid
			Percent
Strongly Agree	81	56.25	56.25
Agree	59	40.97	40.97
Neutral	4	2.78	2.78
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	144	100.00	100.00




### As a result of this activity, I have learned new strategies for patient care:

Label	Frequency	Percent	Valid
			Percent
Strongly Agree	75	52.08	52.08
Agree	59	40.97	40.97
Neutral	10	6.94	6.94
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	144	100.00	100.00




#### How likely are you to implement these new strategies in your practice?

Label	Frequency	Percent	Valid
			Percent
Very likely	92	63.89	66.67
Somewhat likely	34	23.61	24.64
Unlikely	0	0.00	0.00
Not applicable	12	8.33	8.70
Total Valid	138	95.83	100.00
Total Missing	6	4.17	
Total	144	100.00	




### When do you intend to implement these new strategies into your practice?

Label	Frequency	Percent	Valid
			Percent
Within 1 month	77	53.47	57.04
1-3 months	37	25.69	27.41
4-6 months	5	3.47	3.70
Not applicable	16	11.11	11.85
Total Valid	135	93.75	100.00
Total Missing	9	6.25	
Total	144	100.00	




### In terms of delivery of the presentation, please rate the effectiveness of the speaker: Robert Busch, MD (Diabetes):

Label	Frequency	Percent	Valid
			Percent
Excellent	94	65.28	65.73
Very Good	41	28.47	28.67
Good	6	4.17	4.20
Fair	2	1.39	1.40
Unsatisfactory	0	0.00	0.00
Total Valid	143	99.31	100.00
Total Missing	1	0.69	
Total	144	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Marjorie Luckey, MD (Osteo):

Label	Frequency	Percent	Valid
			Percent
Excellent	107	74.31	74.83
Very Good	31	21.53	21.68
Good	4	2.78	2.80
Fair	1	0.69	0.70
Unsatisfactory	0	0.00	0.00
Total Valid	143	99.31	100.00
Total Missing	1	0.69	
Total	144	100.00	




### In terms of delivery of the presentation, please rate the effectiveness of the speaker: Oren Mason, MD (ADHD):

Label	Frequency	Percent	Valid
			Percent
Excellent	70	48.61	50.36
Very Good	47	32.64	33.81
Good	19	13.19	13.67
Fair	2	1.39	1.44
Unsatisfactory	1	0.69	0.72
Total Valid	139	96.53	100.00
Total Missing	5	3.47	
Total	144	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Elizabeth Jackson, MD (A Fib):

Label	Frequency	Percent	Valid
			Percent
Excellent	86	59.72	62.77
Very Good	37	25.69	27.01
Good	12	8.33	8.76
Fair	1	0.69	0.73
Unsatisfactory	1	0.69	0.73
Total Valid	137	95.14	100.00
Total Missing	7	4.86	
Total	144	100.00	




### In terms of delivery of the presentation, please rate the effectiveness of the speaker: Charles Burger, MD (PAH):

Label	Frequency	Percent	Valid
			Percent
Excellent	75	52.08	58.59
Very Good	39	27.08	30.47
Good	11	7.64	8.59
Fair	1	0.69	0.78
Unsatisfactory	2	1.39	1.56
Total Valid	128	88.89	100.00
Total Missing	16	11.11	
Total	144	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Robert Sandhaus, MD (AAT):

Label	Frequency	Percent	Valid
			Percent
Excellent	78	54.17	65.55
Very Good	29	20.14	24.37
Good	9	6.25	7.56
Fair	2	1.39	1.68
Unsatisfactory	1	0.69	0.84
Total Valid	119	82.64	100.00
Total Missing	25	17.36	
Total	144	100.00	




### In terms of delivery of the presentation, please rate the effectiveness of the speaker: Gary Lichtenstein, MD (IBD):

Label	Frequency	Percent	Valid
			Percent
Excellent	78	54.17	77.23
Very Good	19	13.19	18.81
Good	4	2.78	3.96
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	101	70.14	100.00
Total Missing	43	29.86	
Total	144	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Robert Busch, MD (Diabetes):

Label	Frequency	Percent	Valid
			Percent
Excellent	116	80.56	81.69
Very Good	19	13.19	13.38
Good	6	4.17	4.23
Fair	1	0.69	0.70
Unsatisfactory	0	0.00	0.00
Total Valid	142	98.61	100.00
Total Missing	2	1.39	
Total	144	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Marjorie Luckey, MD (Osteo):

Label	Frequency	Percent	Valid
			Percent
Excellent	120	83.33	83.92
Very Good	19	13.19	13.29
Good	4	2.78	2.80
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	143	99.31	100.00
Total Missing	1	0.69	
Total	144	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Oren Mason, MD (ADHD):

Label	Frequency	Percent	Valid
			Percent
Excellent	108	75.00	76.06
Very Good	23	15.97	16.20
Good	10	6.94	7.04
Fair	1	0.69	0.70
Unsatisfactory	0	0.00	0.00
Total Valid	142	98.61	100.00
Total Missing	2	1.39	
Total	144	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Elizabeth Jackson, MD (A Fib):

Label	Frequency	Percent	Valid
			Percent
Excellent	110	76.39	77.46
Very Good	23	15.97	16.20
Good	7	4.86	4.93
Fair	1	0.69	0.70
Unsatisfactory	1	0.69	0.70
Total Valid	142	98.61	100.00
Total Missing	2	1.39	
Total	144	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Charles Burger, MD (PAH):

Label	Frequency	Percent	Valid
			Percent
Excellent	97	67.36	80.17
Very Good	20	13.89	16.53
Good	4	2.78	3.31
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	121	84.03	100.00
Total Missing	23	15.97	
Total	144	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Robert Sandhaus, MD (AAT):

Label	Frequency	Percent	Valid
			Percent
Excellent	95	65.97	79.83
Very Good	19	13.19	15.97
Good	4	2.78	3.36
Fair	1	0.69	0.84
Unsatisfactory	0	0.00	0.00
Total Valid	119	82.64	100.00
Total Missing	25	17.36	
Total	144	100.00	




# To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Gary Lichtenstein, MD (IBD):

Label	Frequency	Percent	Valid
			Percent
Excellent	90	62.50	86.54
Very Good	12	8.33	11.54
Good	2	1.39	1.92
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	104	72.22	100.00
Total Missing	40	27.78	
Total	144	100.00	




## Which statement(s) best reflects your reasons for participating in this activity:

Label	Frequency	Percent	Valid
			Percent
Topics covered	103	71.53	71.53
Location/ease of	112	77.78	77.78
access			
Faculty	31	21.53	21.53
Earn CME credits	126	87.50	87.50
Total Valid	144	100.00	100.00



#### Future CME activities concerning this subject matter are necessary:

Label	Frequency	Percent	Valid
			Percent
Strongly agree	59	40.97	42.14
Agree	70	48.61	50.00
Neutral	11	7.64	7.86
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	140	97.22	100.00
Total Missing	4	2.78	
Total	144	100.00	



#### What is your professional degree?

Comment	
RPH	
DMD	

#### What is your specialty?

Comment
Hospitalist
Occupational Medicine
Internal Medicine
Urology
Pediatrics
Neurosurgery
Internal Medicine
Surgery
Hospitalist
Pediatrics
Internal medicine
Hem/Oncology
Anesthesiology
House calls
Hem/Oncology
Pain Management
Internal Medicine
Research
Hospitalist
Hospitalist
Urgent Care
Geriatrics

## As a result of this activity, I have learned new strategies for patient care. List these strategies:

Comment
AATD testing
Screen with Dexa
Implement screening
ADHD strategies and PAH strategies
Screen for AAT and CHADS in Afib
Diagnosis and treatments
CHADS screening
Early treatment of DM

Comment Osteoporosis screening and treatment Atrial Fib-new medications and IBD Check AAT levels in COPD patients Use more CHAD More likely to use FRAX tool and CHAD score IBD and DM management Use of combination therapy Better osteoporosis management Stroke prevention in A fib patients Anticoagulation in Atrial fibrillation Treating aggressive DM2 early Early aggressive diabetes treatment Combine insulin and drug therapy in diabetes. Early testing for AAT Develop new tools in management Early combination therapy in DM2 Adult ADHD Use of adjuvant DM therapies and CHADS CHADS 2 score Treat diabetes earlier and more aggressively Diagnose ADHD in correct fashion Use of medications appropriately More aggressive treatments as well as screening Using the FRAX tool Screen more patients for AAT Use CHADS score to risk stratify Treatment strategies in DM Screening COPD patients for AAT Treat diabetes more aggressively. Use CHADS2 score ADHD assessment Improve my choice of meds for diabetes New meds Diabetes care with new drugs Tailoring treatment for diabetes and screening for A fib Adult ADHD treatment Early correct diagnosis and treatment Check and follow for AATD Use of CHADS scoring. Consider PAH in patients with corrective tissue disease Alternatives to Warfarin Screen for osteoporosis Tests for AATD Use of new drugs fro A Fib Treatment of pulmonary hypertension Screening osteoporosis for all women over 65. How to use CHADS2 score

Treatment

Comment
Screening for AAT
Better understanding of the disease process
Use CHADS score more and FRAX tool
Use FRAX tool for osteoporosis. Test for AAT in COPD

### What topics would you like to see offered as CME activities in the future?

Comment
Rheumatoid arthritis and COPD/Asthma
More pediatric topics
Urologic topics
Depression
Chronic pain and asthma
Substance abuse
Hypertension
Any primary care topics
CHF management and depression
Infectious disease
Depression screening
Heart failure
Connective tissue disorder
Hypertension and RA
CAD and HTN
PSA and prostate cancer
Urology
Dermatology
Neurological diagnoses
Hypertension and Alzheimer disease
CHF
Hospitalist topics
Low back pain
Cardiology
Hepatitis and pain management and addiction
Hypertension
Asthma
Sleep disorders
Obesity and prostate cancer
More on diabetes
Parkinson's and Alzheimer's
Rheumatology
Pediatric topics
Anemias
Pediatric topics

Comment COPD management Dermatology Neurology update Headaches Chronic prostatitis CHF management **COPD** What is new in infectious disease Cardiology HTN and COPD Depression Diabetes management Obesity Genetics and genome Social media use Obesity and metabolic syndrome Celiac disease Stroke Lung transplant Dementia and pain management HTN management and treatment challenges Off label use of drugs Pain management in hospice patients Heart failure treatment Women' health Dementia treatment Dementia Oral manifestations of systemic disease

Dermatology and ENT topics

#### Additional comments:

Additional comments:
Comment
Thank you
Great day
Excellent
It would be great is parking was taken care of
Thank you for the handout!
Very cold
Terrific speakers
IThank you
Well done-thank you
Very good meeting
I have enjoyed this conference
More time for questions
Very good conference and I learned a lot-thank you
Very well done-thanks
Good course
This was an excellent conference-thank you
Good program
Was very helpful-thanks
Great
I appreciated the use of brand names in addition to generic drug names.
Good interaction
Thanks
Great course
Thank you
Excellent program
More CME's for nurses
Excellent as always
Excellent conference
Very well done
Excellent course and location
Group discussion was good
Great conference
Good location
Very good conference
Excellent
The room was cold
Well organized conference
The room was very cold
Thank you
Good topics.
Thanks!

#### **Item Statistics:**

	Title	Specialty	Learning	Learning	Learning	Learning	Learning
			Objectives1	Objectives2	Objectives3	Objectives4	Objectives5
Mean	1.58	2.58	1.13	1.06	1.26	1.14	1.27
Variance	1.34	7.87	0.12	0.06	0.22	0.13	0.24
Standard Deviation	1.16	2.80	0.34	0.24	0.47	0.37	0.49
Standard Error	0.10	0.23	0.03	0.02	0.04	0.03	0.04
Minimum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Maximum	6.00	8.00	2.00	2.00	3.00	3.00	3.00
Median	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Range	5.00	7.00	1.00	1.00	2.00	2.00	2.00

	Learning	Learning	Overall Activity	Enhancing My	Improving My	Patient Care	Make Changes
	Objectives6	Objectives7		Confidence	Knowledge		
Mean	1.27	1.17	1.56	1.49	1.47	1.55	1.51
Variance	0.26	0.18	0.47	0.32	0.31	0.39	0.78
Standard Deviation	0.51	0.42	0.69	0.57	0.55	0.62	0.88
Standard Error	0.05	0.04	0.06	0.05	0.05	0.05	0.08
Minimum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Maximum	3.00	3.00	4.00	3.00	3.00	3.00	4.00
Median	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Range	2.00	2.00	3.00	2.00	2.00	2.00	3.00

	Implement	Robert Busch	Marjorie	Oren Mason	Elizabeth	Charles Burger	Robert
	New Strategies	MD (Diabetes)	Luckey MD	MD (ADHD)	Jackson MD {A	MD {PAH}	Sandhaus MD
			{Osteo}		Fib}		{AAT}
Mean	1.70	4.59	4.71	4.32	4.50	4.44	4.52
Variance	1.00	0.41	0.31	0.67	0.56	0.66	0.61
Standard Deviation	1.00	0.64	0.55	0.82	0.75	0.81	0.78
Standard Error	0.09	0.05	0.05	0.07	0.06	0.07	0.07
Minimum	1.00	2.00	2.00	1.00	1.00	1.00	1.00
Maximum	4.00	5.00	5.00	5.00	5.00	5.00	5.00
Median	1.00	5.00	5.00	5.00	5.00	5.00	5.00
Range	3.00	3.00	3.00	4.00	4.00	4.00	4.00

	Gary	Robert Busch	Marjorie	Oren Mason	Elizabeth	Charles Burger	Robert
	Lichtenstein	MD (Diabetes)	Luckey MD	MD {ADHD}	Jackson MD {A	MD {PAH} Bias	Sandhaus MD
	MD {IBD}	Bias	(Osteo) Bias	Bias	Fib} Bias		{AAT} Bias
Mean	4.73	4.76	4.81	4.68	4.69	4.77	4.75
Variance	0.28	0.31	0.21	0.40	0.44	0.25	0.31
Standard Deviation	0.53	0.56	0.46	0.64	0.67	0.50	0.56
Standard Error	0.05	0.05	0.04	0.05	0.06	0.05	0.05
Minimum	3.00	2.00	3.00	2.00	1.00	3.00	2.00
Maximum	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Median	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Range	2.00	3.00	2.00	3.00	4.00	2.00	3.00

	Gary Lichtenstein MD {IBD}	Reasons for Participating	Future CME Activities
	Bias		
Mean	4.85	-	1.66
Variance	0.17	<del>-</del>	0.39
Standard Deviation	0.41	-	0.62
Standard Error	0.04	<del>-</del>	0.05
Minimum	3.00	-	1.00
Maximum	5.00	-	3.00
Median	5.00	-	2.00
Range	2.00	<del>-</del> _	2.00